User-centred assistive SystEm for arm Functions in neUromuscuLar subjects (USEFUL): a randomized controlled study.


Journal

Journal of neuroengineering and rehabilitation
ISSN: 1743-0003
Titre abrégé: J Neuroeng Rehabil
Pays: England
ID NLM: 101232233

Informations de publication

Date de publication:
06 01 2021
Historique:
received: 14 07 2020
accepted: 01 12 2020
entrez: 7 1 2021
pubmed: 8 1 2021
medline: 26 5 2021
Statut: epublish

Résumé

Upper limb assistive devices can compensate for muscular weakness and empower the user in the execution of daily activities. Multiple devices have been recently proposed but there is still a lack in the scientific comparison of their efficacy. We conducted a cross-over multi-centric randomized controlled trial to assess the functional improvement at the upper limb level of two arms supports on 36 patients with muscular dystrophy. Participants tested a passive device (i.e., Wrex by Jaeco) and a semi-active solution for gravity compensation (i.e., Armon Ayura). We evaluated devices' effectiveness with an externally-assessed scale (i.e., Performance of the Upper Limb-PUL-module), a self-perceived scale (i.e., Abilhand questionnaire), and a usability scale (i.e., System Usability Scale). Friedman's test was used to assess significant functional gain for PUL module and Abilhand questionnaire. Moreover, PUL changes were compared by means of the Friedman's test. Most of the patients improved upper limb function with the use of arm supports (median PUL scores increase of 1-3 points). However, the effectiveness of each device was related to the level of residual ability of the end-user. Slightly impaired patients maintained the same independence without and with assistive devices, even if they reported reduced muscular fatigue for both devices. Moderately impaired patients enhanced their arm functionality with both devices, and they obtained higher improvements with the semi-active one (median PUL scores increase of 9 points). Finally, severely impaired subjects benefited only from the semi-active device (median PUL scores increase of 12 points). Inadequate strength was recognized as a barrier to passive devices. The usability, measured by the System Usability Scale, was evaluated by end-users "good" (70/100 points) for the passive, and "excellent" (80/100 points) for the semi-active device. This study demonstrated that assistive devices can improve the quality of life of people suffering from muscular dystrophy. The use of passive devices, despite being low cost and easy to use, shows limitations in the efficacy of the assistance to daily tasks, limiting the assistance to a predefined horizontal plane. The addition of one active degree of freedom improves efficacy and usability especially for medium to severe patients. Further investigations are needed to increase the evidence on the effect of arm supports on quality of life and diseases' progression in subjects with degenerative disorders. Trial registration clinicaltrials.gov, NCT03127241, Registered 25th April 2017. The clinical trial was also registered as a post-market study at the Italian Ministry of Health.

Sections du résumé

BACKGROUND
Upper limb assistive devices can compensate for muscular weakness and empower the user in the execution of daily activities. Multiple devices have been recently proposed but there is still a lack in the scientific comparison of their efficacy.
METHODS
We conducted a cross-over multi-centric randomized controlled trial to assess the functional improvement at the upper limb level of two arms supports on 36 patients with muscular dystrophy. Participants tested a passive device (i.e., Wrex by Jaeco) and a semi-active solution for gravity compensation (i.e., Armon Ayura). We evaluated devices' effectiveness with an externally-assessed scale (i.e., Performance of the Upper Limb-PUL-module), a self-perceived scale (i.e., Abilhand questionnaire), and a usability scale (i.e., System Usability Scale). Friedman's test was used to assess significant functional gain for PUL module and Abilhand questionnaire. Moreover, PUL changes were compared by means of the Friedman's test.
RESULTS
Most of the patients improved upper limb function with the use of arm supports (median PUL scores increase of 1-3 points). However, the effectiveness of each device was related to the level of residual ability of the end-user. Slightly impaired patients maintained the same independence without and with assistive devices, even if they reported reduced muscular fatigue for both devices. Moderately impaired patients enhanced their arm functionality with both devices, and they obtained higher improvements with the semi-active one (median PUL scores increase of 9 points). Finally, severely impaired subjects benefited only from the semi-active device (median PUL scores increase of 12 points). Inadequate strength was recognized as a barrier to passive devices. The usability, measured by the System Usability Scale, was evaluated by end-users "good" (70/100 points) for the passive, and "excellent" (80/100 points) for the semi-active device.
CONCLUSIONS
This study demonstrated that assistive devices can improve the quality of life of people suffering from muscular dystrophy. The use of passive devices, despite being low cost and easy to use, shows limitations in the efficacy of the assistance to daily tasks, limiting the assistance to a predefined horizontal plane. The addition of one active degree of freedom improves efficacy and usability especially for medium to severe patients. Further investigations are needed to increase the evidence on the effect of arm supports on quality of life and diseases' progression in subjects with degenerative disorders. Trial registration clinicaltrials.gov, NCT03127241, Registered 25th April 2017. The clinical trial was also registered as a post-market study at the Italian Ministry of Health.

Identifiants

pubmed: 33407580
doi: 10.1186/s12984-020-00794-z
pii: 10.1186/s12984-020-00794-z
pmc: PMC7789525
doi:

Banques de données

ClinicalTrials.gov
['NCT03127241']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4

Références

J Rehabil Res Dev. 2006 Aug-Sep;43(5):583-90
pubmed: 17123200
PLoS One. 2018 Jun 20;13(6):e0199223
pubmed: 29924848
Neuropediatrics. 2017 Aug;48(4):262-272
pubmed: 28427100
IEEE Trans Neural Syst Rehabil Eng. 2016 Dec;24(12):1277-1283
pubmed: 28055882
Annu Int Conf IEEE Eng Med Biol Soc. 2019 Jul;2019:4431-4435
pubmed: 31946849
J Neurol Neurosurg Psychiatry. 2010 May;81(5):506-12
pubmed: 19726413
Neuromuscul Disord. 2019 Aug;29(8):651-656
pubmed: 31443952
J Neuroeng Rehabil. 2017 Jul 12;14(1):73
pubmed: 28701169
Phys Med Rehabil Clin N Am. 2012 Aug;23(3):675-87
pubmed: 22938881
J Rehabil Res Dev. 2016;53(6):1139-1150
pubmed: 28355038
Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:1573-6
pubmed: 19963513
J Neuroeng Rehabil. 2015 Sep 18;12:83
pubmed: 26385658
J Neurol. 2014 Jul;261(7):1269-88
pubmed: 24687893
Am J Occup Ther. 2018 Mar/Apr;72(2):7202345010p1-7202345010p5
pubmed: 29426391
Front Bioeng Biotechnol. 2020 Jan 24;7:450
pubmed: 32039171
Disabil Rehabil Assist Technol. 2020 Sep 26;:1-14
pubmed: 32981390
Disabil Rehabil. 2017 Jul;39(14):1408-1413
pubmed: 27347814
PLoS One. 2020 Sep 28;15(9):e0239064
pubmed: 32986757
J Rehabil Med. 2011 Sep;43(9):770-5
pubmed: 21826385
IEEE Trans Neural Syst Rehabil Eng. 2007 Jun;15(2):244-51
pubmed: 17601194
IEEE Int Conf Rehabil Robot. 2013 Jun;2013:6650368
pubmed: 24187187
J Rehabil Med. 2008 Aug;40(8):665-71
pubmed: 19020701
Dev Med Child Neurol. 2013 Nov;55(11):1038-45
pubmed: 23902233
Muscle Nerve. 2017 Jan;55(1):55-68
pubmed: 27184587
J Rehabil Res Dev. 2013;50(1):61-70
pubmed: 23516084
Neuromuscul Disord. 2014 Mar;24(3):201-6
pubmed: 24440357
Muscle Nerve. 2019 Oct;60(4):419-424
pubmed: 31298728
Disabil Rehabil. 2014;36(22):1918-23
pubmed: 24499260
Disabil Rehabil Assist Technol. 2020 Apr 15;:1-10
pubmed: 32293211
J Neuromuscul Dis. 2018;5(3):359-372
pubmed: 29991140
J Neuromuscul Dis. 2015 Jul 22;2(s2):S7-S19
pubmed: 27858764

Auteurs

Valeria Longatelli (V)

NeuroEngineering And medical Robotics Laboratory, NearLab, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Via Giuseppe Colombo 40, 20133, Milan, Italy.

Alberto Antonietti (A)

NeuroEngineering And medical Robotics Laboratory, NearLab, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Via Giuseppe Colombo 40, 20133, Milan, Italy.

Emilia Biffi (E)

Scientific Institute IRCCS E. Medea, Via Don Luigi Monza 20, 23842, Bosisio Parini, Italy.

Eleonora Diella (E)

Scientific Institute IRCCS E. Medea, Via Don Luigi Monza 20, 23842, Bosisio Parini, Italy.

Maria Grazia D'Angelo (MG)

Scientific Institute IRCCS E. Medea, Via Don Luigi Monza 20, 23842, Bosisio Parini, Italy.

Mauro Rossini (M)

Valduce Hospital, Villa Beretta Rehabilitation Center, Via Nazario Sauro 17, 23845, Costa Masnaga, Italy.

Franco Molteni (F)

Valduce Hospital, Villa Beretta Rehabilitation Center, Via Nazario Sauro 17, 23845, Costa Masnaga, Italy.

Marco Bocciolone (M)

Department of Mechanical Engineering, Politecnico di Milano, Via Giuseppe La Masa 1, 20156, Milan, Italy.

Alessandra Pedrocchi (A)

NeuroEngineering And medical Robotics Laboratory, NearLab, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Via Giuseppe Colombo 40, 20133, Milan, Italy.

Marta Gandolla (M)

NeuroEngineering And medical Robotics Laboratory, NearLab, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Via Giuseppe Colombo 40, 20133, Milan, Italy. marta.gandolla@polimi.it.
Department of Mechanical Engineering, Politecnico di Milano, Via Giuseppe La Masa 1, 20156, Milan, Italy. marta.gandolla@polimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH